Close up of cancer cell with metastatis



Zetagen has discovered and patented the discovery of a new molecular pathway of a well establish small molecule, as well as, novel carriers and NEW chemical entities. Through this new mechanism of action (MOA), which is a novel molecular pathway, this small molecule, precisely-dosed, delivered to the affected area through a proprietary drug-eluting carrier, stimulates stem cells, activating cells to grow healthy bone known as “osteoblasts”, and inhibits cells associated with bone degradation called “osteoclasts”.
Our product, ZetaMet™ (Zeta-BC-003) has thus far demonstrated its ability to resolve existing metastatic bone lesions, inhibit pain, and stimulate targeted bone regeneration.

Zetagen has performed invitro human mesenchymal stem cells (hMSC), controlled and GLP preclinical studies substantiating these claims. These data have been submitted to Health Canada, the FDA and the TGA.


Learn more about ZetaMet™ (Zeta-BC-003)

About Zetamet™ (Zeta-BC-003)